MADRID — Day of the week, age, snacking, and being more engaged with smart insulin pens are important factors that affect ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 36% surge in Q2 revenue, driven by new product launches ...

Eli Lilly announced positive results from two phase 3 clinical trials (QWINT-1 and QWINT-3), which evaluated a new once-weekly insulin called efsitora alfa (efsitora) for adults with type 2 diabetes.

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in ...

Eli Lilly (NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market.